299 related articles for article (PubMed ID: 23421411)
1. Transient receptor potential vanilloid 1 as a therapeutic target in analgesia.
Szolcsányi J; Pintér E
Expert Opin Ther Targets; 2013 Jun; 17(6):641-57. PubMed ID: 23421411
[TBL] [Abstract][Full Text] [Related]
2. Multisteric TRPV1 nocisensor: a target for analgesics.
Szolcsányi J; Sándor Z
Trends Pharmacol Sci; 2012 Dec; 33(12):646-55. PubMed ID: 23068431
[TBL] [Abstract][Full Text] [Related]
3. Capsaicin and sensory neurones: a historical perspective.
Szolcsányi J
Prog Drug Res; 2014; 68():1-37. PubMed ID: 24941663
[TBL] [Abstract][Full Text] [Related]
4. Targeting TRPV1 for pain relief: limits, losers and laurels.
Szallasi A; Sheta M
Expert Opin Investig Drugs; 2012 Sep; 21(9):1351-69. PubMed ID: 22780443
[TBL] [Abstract][Full Text] [Related]
5. Design and characterization of a noncompetitive antagonist of the transient receptor potential vanilloid subunit 1 channel with in vivo analgesic and anti-inflammatory activity.
García-Martínez C; Fernández-Carvajal A; Valenzuela B; Gomis A; Van Den Nest W; Ferroni S; Carreño C; Belmonte C; Ferrer-Montiel A
J Pain; 2006 Oct; 7(10):735-46. PubMed ID: 17018334
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic potential of vanilloid receptor TRPV1 agonists and antagonists as analgesics: Recent advances and setbacks.
Wong GY; Gavva NR
Brain Res Rev; 2009 Apr; 60(1):267-77. PubMed ID: 19150372
[TBL] [Abstract][Full Text] [Related]
7. Amelioration of neuropathic pain by novel transient receptor potential vanilloid 1 antagonist AS1928370 in rats without hyperthermic effect.
Watabiki T; Kiso T; Kuramochi T; Yonezawa K; Tsuji N; Kohara A; Kakimoto S; Aoki T; Matsuoka N
J Pharmacol Exp Ther; 2011 Mar; 336(3):743-50. PubMed ID: 21098091
[TBL] [Abstract][Full Text] [Related]
8. Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).
Lee Y; Hong S; Cui M; Sharma PK; Lee J; Choi S
Expert Opin Ther Pat; 2015 Mar; 25(3):291-318. PubMed ID: 25666693
[TBL] [Abstract][Full Text] [Related]
9. Capsaicin (TRPV1 Agonist) therapy for pain relief: farewell or revival?
Knotkova H; Pappagallo M; Szallasi A
Clin J Pain; 2008 Feb; 24(2):142-54. PubMed ID: 18209521
[TBL] [Abstract][Full Text] [Related]
10. Repeated dosing of ABT-102, a potent and selective TRPV1 antagonist, enhances TRPV1-mediated analgesic activity in rodents, but attenuates antagonist-induced hyperthermia.
Honore P; Chandran P; Hernandez G; Gauvin DM; Mikusa JP; Zhong C; Joshi SK; Ghilardi JR; Sevcik MA; Fryer RM; Segreti JA; Banfor PN; Marsh K; Neelands T; Bayburt E; Daanen JF; Gomtsyan A; Lee CH; Kort ME; Reilly RM; Surowy CS; Kym PR; Mantyh PW; Sullivan JP; Jarvis MF; Faltynek CR
Pain; 2009 Mar; 142(1-2):27-35. PubMed ID: 19135797
[TBL] [Abstract][Full Text] [Related]
11. Differential effects of TRPV channel block on polymodal activation of rat cutaneous nociceptors in vitro.
St Pierre M; Reeh PW; Zimmermann K
Exp Brain Res; 2009 Jun; 196(1):31-44. PubMed ID: 19404626
[TBL] [Abstract][Full Text] [Related]
12. Transient receptor potential vanilloid-1 antagonists: a survey of recent patent literature.
Voight EA; Kort ME
Expert Opin Ther Pat; 2010 Sep; 20(9):1107-22. PubMed ID: 20586701
[TBL] [Abstract][Full Text] [Related]
13. Repeated administration of vanilloid receptor TRPV1 antagonists attenuates hyperthermia elicited by TRPV1 blockade.
Gavva NR; Bannon AW; Hovland DN; Lehto SG; Klionsky L; Surapaneni S; Immke DC; Henley C; Arik L; Bak A; Davis J; Ernst N; Hever G; Kuang R; Shi L; Tamir R; Wang J; Wang W; Zajic G; Zhu D; Norman MH; Louis JC; Magal E; Treanor JJ
J Pharmacol Exp Ther; 2007 Oct; 323(1):128-37. PubMed ID: 17652633
[TBL] [Abstract][Full Text] [Related]
14. Antinociceptive desensitizing actions of TRPV1 receptor agonists capsaicin, resiniferatoxin and N-oleoyldopamine as measured by determination of the noxious heat and cold thresholds in the rat.
Bölcskei K; Tékus V; Dézsi L; Szolcsányi J; Petho G
Eur J Pain; 2010 May; 14(5):480-6. PubMed ID: 19800272
[TBL] [Abstract][Full Text] [Related]
15. Forty years in capsaicin research for sensory pharmacology and physiology.
Szolcsányi J
Neuropeptides; 2004 Dec; 38(6):377-84. PubMed ID: 15567473
[TBL] [Abstract][Full Text] [Related]
16. 7-tert-Butyl-6-(4-chloro-phenyl)-2-thioxo-2,3-dihydro-1H-pyrido[2,3-d]pyrimidin-4-one, a classic polymodal inhibitor of transient receptor potential vanilloid type 1 with a reduced liability for hyperthermia, is analgesic and ameliorates visceral hypersensitivity.
Nash MS; McIntyre P; Groarke A; Lilley E; Culshaw A; Hallett A; Panesar M; Fox A; Bevan S
J Pharmacol Exp Ther; 2012 Aug; 342(2):389-98. PubMed ID: 22566669
[TBL] [Abstract][Full Text] [Related]
17. (R)-(5-tert-butyl-2,3-dihydro-1H-inden-1-yl)-3-(1H-indazol-4-yl)-urea (ABT-102) blocks polymodal activation of transient receptor potential vanilloid 1 receptors in vitro and heat-evoked firing of spinal dorsal horn neurons in vivo.
Surowy CS; Neelands TR; Bianchi BR; McGaraughty S; El Kouhen R; Han P; Chu KL; McDonald HA; Vos M; Niforatos W; Bayburt EK; Gomtsyan A; Lee CH; Honore P; Sullivan JP; Jarvis MF; Faltynek CR
J Pharmacol Exp Ther; 2008 Sep; 326(3):879-88. PubMed ID: 18515644
[TBL] [Abstract][Full Text] [Related]
18. Clinical development of TRPV1 antagonists: targeting a pivotal point in the pain pathway.
Gunthorpe MJ; Chizh BA
Drug Discov Today; 2009 Jan; 14(1-2):56-67. PubMed ID: 19063991
[TBL] [Abstract][Full Text] [Related]
19. Polymodal Transient Receptor Potential Vanilloid Type 1 Nocisensor: Structure, Modulators, and Therapeutic Applications.
Cui M; Gosu V; Basith S; Hong S; Choi S
Adv Protein Chem Struct Biol; 2016; 104():81-125. PubMed ID: 27038373
[TBL] [Abstract][Full Text] [Related]
20. Evidence for the role of lipid rafts and sphingomyelin in Ca2+-gating of Transient Receptor Potential channels in trigeminal sensory neurons and peripheral nerve terminals.
Sághy É; Szőke É; Payrits M; Helyes Z; Börzsei R; Erostyák J; Jánosi TZ; Sétáló G; Szolcsányi J
Pharmacol Res; 2015 Oct; 100():101-16. PubMed ID: 26238178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
